Next-Generation ADC Breakthrough
Recently, there has been some news that is quite eye-catching.On November 19, 2025, ADC Biotechnology Company Lifordi Immunotherapeutics announced the completion of a new round of strategic financing of $42 million. The funds are mainly used for ADC beyond tumors— LFD-200, which targets VISTA, one of the most competitive emerging targets (for both cancer and … Read more